Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
NovaBay Pharmaceuticals (AMEX:NBY) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
NovaBay Pharmaceuticals beat estimated earnings by 30.0%, reporting an EPS of $-0.21 versus an estimate of $-0.3.
Revenue was up $84 thousand from the same period last year.
Last quarter the company beat on EPS by $0.03 which was followed by a 8.0% drop in the share price the next day.
Here's a look at NovaBay Pharmaceuticals's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -0.40 | -0.55 | -0.91 | -0.17 |
EPS Actual | -0.37 | -1.27 | -0.85 | -1.47 |
Revenue Estimate | 3.55M | 3.67M | 3.20M | 5.10M |
Revenue Actual | 3.27M | 4.61M | 3.12M | 3.64M |
To track all earnings releases for NovaBay Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: NBY